Breaking News

Neurocrine Biosciences & Sosei Group Collaborate to Develop Treatment for Neuropsychiatric Disorders

Sosei Heptares receives $100 million upfront, ongoing R&D funding and up to $2.6 billion in potential development, regulatory and commercial milestone payments.

Author Image

By: Charlie Sternberg

Associate Editor

Neurocrine Biosciences Inc. and Sosei Group Corporation have signed a strategic collaboration and licensing agreement to develop novel muscarinic receptor agonists, which Neurocrine Biosciences intends to study in the treatment for schizophrenia, dementia and other neuropsychiatric disorders.   Under the terms of the agreement, Neurocrine Biosciences gains development and commercialization rights to a broad portfolio of novel clinical and preclinical subtype-selective muscarinic M4, M1 and dual ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters